cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1636Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПериндоприла аргинин: новая соль ингибитора ангиотензин-превращающего фермента расширяет возможности примененияPerindopril arginine: a new ACE inhibitor salt increases therapeutic potentialКарповЮ. А.KarpovYu. A.yuri_karpov@inbox.ruФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологии, г. МоскваRussian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow200820122008766472Copyright © Карпов Ю.А., 20082008Карпов Ю.А.Karpov Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1636ингибиторы ангиотензин-превращающего ферментатертбутиламиновая соль периндоприлааргининовая соль периндоприластабильностьбиоэквивалентностьACE inhibitorsperindopril tert butylamineperindopril argininestabilitybioequivalenceReferencesCurran M.P., McCormack P.L., Simpson D. Perindopril A review of its use in patients with and at risk of developing coronary artery disease. Drugs 2006; 66(2): 235-55.Curran M.P., McCormack P.L., Simpson D. Perindopril A review of its use in patients with and at risk of developing coronary artery disease. Drugs 2006; 66(2): 235-55.The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.Sever P.S., Dahlof B., Poulter N.R., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Sever P.S., Dahlof B., Poulter N.R., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.Ferrari R. for the PREAMI investigators. Effects of ACE inhibition with perindopril on left ventricular remodeling and clinical outcome. Arch. Intern. Med. 2006; 166: 659-666.Ferrari R. for the PREAMI investigators. Effects of ACE inhibition with perindopril on left ventricular remodeling and clinical outcome. Arch. Intern. Med. 2006; 166: 659-666.Cleland J.G.F., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF). Eur. Heart J. 2006; 27:2338-45.Cleland J.G.F., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF). Eur. Heart J. 2006; 27:2338-45.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-40.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-40.Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovascar. Ther. 2005; 3(1): 15-29.Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovascar. Ther. 2005; 3(1): 15-29.Physicians Desk Reference, 55th edn. Montvale, NJ: Medical Economics Company 2001.Physicians Desk Reference, 55th edn. Montvale, NJ: Medical Economics Company 2001.Poggi L., Renucci J.F., Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can. J. Cardiol. 1994; 10(Suppl. D): 21D-4.Poggi L., Renucci J.F., Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can. J. Cardiol. 1994; 10(Suppl. D): 21D-4.Julius S., Cohn J.N., Neutel J., et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. Clin. Hypertens. 2004; 6 (1): 10-7.Julius S., Cohn J.N., Neutel J., et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. Clin. Hypertens. 2004; 6 (1): 10-7.Карпов Ю.А., Шальнова С.А., Деев А.Д. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) -безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32-8.Карпов Ю.А., Шальнова С.А., Деев А.Д. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) -безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32-8.Карпов Ю.А., Деев А.Д. от имени врачей-участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ -Престариум в лечении артериальной гипертонии: антигипертензивная эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007; 7: 35-40.Карпов Ю.А., Деев А.Д. от имени врачей-участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ -Престариум в лечении артериальной гипертонии: антигипертензивная эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007; 7: 35-40.Ghiadoni L., Magagna A., Versari D., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.Ghiadoni L., Magagna A., Versari D., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.Zhuo J.L., Froomes P., Casley D., et al. Perindopril chronically inhibits angiotensin-convertong enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96(1): 174-82.Zhuo J.L., Froomes P., Casley D., et al. Perindopril chronically inhibits angiotensin-convertong enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96(1): 174-82.Ceconi C., Fox K., Remme W.J., et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2006; 2006.10.021 DOI: 10.1016/j.cardioresCeconi C., Fox K., Remme W.J., et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 2006; 2006.10.021 DOI: 10.1016/j.cardioresBots M.L., Remme W.J., Luscher T.F., et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc. Drugs ther. 2007; DOI 10.1007/s10557-007-6041-3.Bots M.L., Remme W.J., Luscher T.F., et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc. Drugs ther. 2007; DOI 10.1007/s10557-007-6041-3.Rodriguez-Granillo G.A. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe Perindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and Intravascular Ultrasound Evaluation [PERSPECTIVE] Study). Am. J. Cardiol. 2007; 100: 159-63.Rodriguez-Granillo G.A. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe Perindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and Intravascular Ultrasound Evaluation [PERSPECTIVE] Study). Am. J. Cardiol. 2007; 100: 159-63.Rodriguez-Granillo G.A., Serruys P.W., Garcia-Garcia H.M., et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92: 388-91.Rodriguez-Granillo G.A., Serruys P.W., Garcia-Garcia H.M., et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92: 388-91.Чазов Е.И., Оганов Р.Г., и др. Диагностика и лечение стабильной стенокардии. Российские рекомендации. // Кардиоваск. тер. профил. 2004. Т. 3. № 4 S1.Чазов Е.И., Оганов Р.Г., и др. Диагностика и лечение стабильной стенокардии. Российские рекомендации. // Кардиоваск. тер. профил. 2004. Т. 3. № 4 S1.Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006; 113: 1-13.Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006; 113: 1-13.Telejko E. Perindopril arginine benefits of f new salt of the ACE inhibitor perindopril. Curr. Med. Res. Opin. 2007; 953-60.Telejko E. Perindopril arginine benefits of f new salt of the ACE inhibitor perindopril. Curr. Med. Res. Opin. 2007; 953-60.ICH Steering Committee. Quality guidelines. Available from www.ich.org/cache/compo/363-272-1.html/[Accessed 9 May 2006].ICH Steering Committee. Quality guidelines. Available from www.ich.org/cache/compo/363-272-1.html/[Accessed 9 May 2006].
The authors declare that there are no conflicts of interest present.